07 July 2020
This webinar has already taken place – please click here to download a recording of the presentation.
For any queries, please contact [email protected].
When: Tuesday 7 July 2020 | 18:00 – 19:00 (BST)
Speakers: Martin MacLean and Hazel Ford
The European Patent Office (EPO) takes a different approach to the US PTO when considering obviousness/inventive step in antibody cases, generally rejecting arguments of structural non-obviousness and relying instead on a more technical consideration of antibody function and effects.
Join Mathys & Squire partners Martin MacLean and Hazel Ford for this free webinar as they discuss the arguments that are most likely to be effective when addressing inventive step objections at the EPO. Focusing on the antibody field, including the effects or advantages that might be relied upon, and the types of evidence that might be deployed to support an antibody claim, our experts will also discuss the breadth of claims that might be obtained in different circumstances based on current EPO practice, and consider when questions of lack of enablement are most likely to arise in an antibody case.
Sign up to our mailing list to receive Mathys Matters, our monthly newsletter covering the latest IP news, industry insights, events and case law.
If you are interested in receiving quarterly newsletters relevant to our core sector groups - IT & engineering ('Inside Wires') and life sciences & chemistry ('Under the Microscope') - please select your preference(s) below:
Please select your practice area(s) of interest: